摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-乙基-3,3-二甲基-哌嗪 | 1225882-54-1

中文名称
1-乙基-3,3-二甲基-哌嗪
中文别名
——
英文名称
1-Ethyl-3,3-dimethylpiperazine
英文别名
——
1-乙基-3,3-二甲基-哌嗪化学式
CAS
1225882-54-1
化学式
C8H18N2
mdl
——
分子量
142.24
InChiKey
OWJOGIXFAWCTHJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338,P302+P352
  • 危险性描述:
    H315,H319,H335

文献信息

  • SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF
    申请人:JAGTAP Prakash
    公开号:US20100261706A1
    公开(公告)日:2010-10-14
    Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or opthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog or derivative.
    本文提供四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物和衍生物,包括含有效量四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物和/或衍生物的组合物以及治疗或预防炎症性疾病、再灌注损伤、糖尿病、糖尿病并发症、器官移植引起的再氧化损伤、缺血症、神经退行性疾病、肾功能衰竭、血管疾病、心血管疾病、眼部或眼科疾病、癌症、早产并发症、心肌病、视网膜病、肾病、造影剂诱导性肾病、神经病和勃起功能障碍或尿失禁的方法,包括向需要的受体施用有效量的四环1H-吲哚[1,2-b]吡啶-2(5H)-酮类似物或衍生物
  • P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
    申请人:Burgey Christopher S
    公开号:US20100266714A1
    公开(公告)日:2010-10-21
    The subject invention relates to novel P2X 3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X 3 receptor subunit modulator.
    本发明涉及一种新型的P2X3受体拮抗剂,它在治疗与疼痛有关的疾病状态中发挥关键作用,特别是可以使用P2X3受体亚单位调节剂治疗的外周疼痛、炎性疼痛或组织损伤疼痛。
  • CXCR3 receptor agonists
    申请人:RECEPTOS LLC
    公开号:US11040954B1
    公开(公告)日:2021-06-22
    Compounds are provided having the structure of the following Formula I: where R, R1, R2, R3a and R3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.
    所提供的化合物具有下式 I 的结构: 其中 R、R1、R2、R3a 和 R3b 如本文所定义。此外,还提供了包含此类化合物的药物组合物,以及与其制造和使用相关的方法。
  • SEPIAPTERIN REDUCTASE INHIBITORS
    申请人:QUARTET MEDICINE, INC.
    公开号:US20170096435A1
    公开(公告)日:2017-04-06
    Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.
  • CXCR3 RECEPTOR AGONISTS
    申请人:CELGENE INTERNATIONAL II SARL
    公开号:US20190345133A1
    公开(公告)日:2019-11-14
    Compounds are provided having the structure of the following Formula I: where R, R 1 , R 2 , R 3 a and R 3b are as defined herein. Pharmaceutical compositions comprising such compounds, as well as methods related to their manufacture and use, are also provided.
查看更多